This Article Full Text Full Text (PDF) Supplemental Data Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Georgitsi, M. Articles by Aaltonen, L. A. Search for Related Content PubMed PubMed Citation Articles by Georgitsi, M. Articles by Aaltonen, L. A. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Related Collections Neuroendocrinology and Pituitary Endocrine Oncology

Large Genomic Deletions in AIP in Pituitary Adenoma Predisposition

Department of Medical Genetics (M.G., E.H., A.K., L.A.A.), 00014 University of Helsinki, Helsinki, Finland; Medical Department III (R.P.), Leipzig University, 04103 Leipzig, Germany; Clinical Genetics (A.V.K.K.), Great Ormond Street National Health Service Trust, London WC1N 3JH, United Kingdom; Departments of Human Genetics, Oncology, and Medicine (M.T.), McGill University, Sir Mortimer B. Davis Jewish General Hospital, H3T 1E2 Montreal, Quebec, Canada; Departments of Clinical Genetics (O.V.) and Internal Medicine (P.S.), Oulu University Hospital, 90029 Oulu, Finland; Department of Endocrinology (T.S.), Helsinki University Central Hospital, 00029 Helsinki, Finland; Department of Internal Medicine (E.D.M.), General Hospital, 31044 Montebelluna, Italy; Department of Medicine and Pharmacology (S.C.), Section of Endocrinology, University of Messina, 98125 Messina, Italy; Division of Endocrinology-Metabolism and Diabetes (S.G.), Cerrahpaçsa Medical Faculty, University of Istanbul, 34303 Istanbul, Turkey; Wessex Clinical Genetics Service (A.L.), Princess Anne Hospital, SO16 5YA Southampton, United Kingdom; Department of Clinical Genetics (L.I.), New Guy’s House, Guy’s Hospital, London SE1 9RT, United Kingdom; Department of Medicine (S.A.), King’s College Hospital, Denmark Hill, London SE5 9RS, United Kingdom; Department of Endocrinology and Diabetes (G.B.), Thomas Addison Unit, London SW17 0QT, United Kingdom; Department of Clinical Genetics (S.H.), St. Georges, University of London, London SW17 ORE, United Kingdom; and Division of Endocrinology (C.A.K.), University of Mississippi Medical Center, Jackson, Mississippi 39216

Address all correspondence and requests for reprints to: Professor Lauri A. Aaltonen, Department of Medical Genetics, Biomedicum Helsinki, P.O. Box 63 (Haartmaninkatu 8), University of Helsinki, 00014 Helsinki, Finland. E-mail: lauri.aaltonen{at}helsinki.fi.

Context: Germline mutations in AIP have been recently shown to cause pituitary adenoma predisposition (PAP). Subsequently, many intragenic germline mutations have been reported, both in familial and in sporadic settings.

Objective: Our objective was to evaluate the possible contribution of large genomic germline AIP deletions, an important mutation type in tumor predisposition syndromes, in PAP.

Design: Here, we applied the multiplex ligation-dependent probe amplification assay to examine whether large genomic AIP or MEN1 alterations account for a subset of PAP cases.

Patients: The study was performed on familial and sporadic pituitary adenoma cases of European origin, which had previously tested negative for germline AIP and MEN1 mutations by sequencing.

Results: Two of 21 pituitary adenoma families (9.5%) were found to harbor an AIP deletion. No copy number changes were detected among 67 sporadic pituitary adenoma patients. No MEN1 deletions were found.

Conclusions: The present study shows that large genomic AIP deletions account for a subset of PAP. Therefore, in suspected PAP cases undergoing counseling and AIP genetic testing, multiplex ligation-dependent probe amplification could be considered if direct sequencing does not identify a mutation.

This article has been cited by other articles:

				J. E Jennings, M. Georgitsi, I. Holdaway, A. F Daly, M. Tichomirowa, A. Beckers, L. A Aaltonen, A. Karhu, and F. J Cameron Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene Eur. J. Endocrinol., November 1, 2009; 161(5): 799 - 804. [Abstract] [Full Text] [PDF]

				M.-L. Jaffrain-Rea, M. Angelini, D. Gargano, M. A Tichomirowa, A. F Daly, J.-F. Vanbellinghen, E. D'Innocenzo, A. Barlier, F. Giangaspero, V. Esposito, et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications Endocr. Relat. Cancer, September 1, 2009; 16(3): 1029 - 1043. [Abstract] [Full Text] [PDF]

				M. Vargiolu, D. Fusco, I. Kurelac, D. Dirnberger, R. Baumeister, I. Morra, A. Melcarne, R. Rimondini, G. Romeo, and E. Bonora The Tyrosine Kinase Receptor RET Interacts in Vivo with Aryl Hydrocarbon Receptor-Interacting Protein to Alter Survivin Availability J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2571 - 2578. [Abstract] [Full Text] [PDF]